Simcere Pharmaceutical Group Limited (HKG:2096)
Hong Kong · Delayed Price · Currency is HKD 11.52
+0.53 (4.82%)
Sep 2, 2026, 10:24 AM HKT
HKG:2096 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 28,225 | 31,071 | 17,653 | 17,611 | 30,914 | 23,628 | |
Market Cap Growth | -19.23% | 76.01% | 0.24% | -43.03% | 30.83% | 1.20% |
Enterprise Value | 25,001 | 29,485 | 15,639 | 16,205 | 29,371 | 23,209 |
Last Close Price | 10.99 | 11.72 | 6.84 | 6.29 | 10.62 | 8.06 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 15.62 | 20.77 | 22.98 | 22.37 | 29.38 | 12.77 |
Forward PE | 12.12 | 16.58 | 14.35 | 12.11 | 29.04 | 26.63 |
PS Ratio | 2.80 | 3.61 | 2.50 | 2.42 | 4.32 | 3.85 |
PB Ratio | 2.58 | 2.97 | 2.33 | 2.21 | 3.83 | 2.98 |
P/TBV Ratio | 3.13 | 3.57 | 2.78 | 2.51 | 4.16 | 3.10 |
P/FCF Ratio | - | 16.78 | 16.25 | - | 27.04 | - |
P/OCF Ratio | - | 13.87 | 11.92 | 105.83 | 20.19 | - |
PEG Ratio | - | 1.12 | 1.12 | 1.12 | 1.12 | 1.12 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.48 | 3.43 | 2.22 | 2.23 | 4.11 | 3.78 |
EV/EBITDA Ratio | 10.35 | 15.41 | 10.62 | 15.90 | 31.86 | 44.76 |
EV/EBIT Ratio | 12.42 | 18.70 | 13.07 | 20.69 | 42.85 | 81.03 |
EV/FCF Ratio | - | 15.92 | 14.39 | - | 25.69 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.12 | 0.13 | 0.17 | 0.20 | 0.21 | 0.25 |
Debt / EBITDA Ratio | 0.56 | 0.66 | 0.83 | 1.43 | 1.72 | 3.50 |
Debt / FCF Ratio | - | 0.71 | 1.18 | - | 1.49 | - |
Net Debt / Equity Ratio | -0.30 | -0.25 | -0.11 | -0.08 | -0.16 | -0.08 |
Net Debt / EBITDA Ratio | -1.36 | -1.39 | -0.54 | -0.64 | -1.37 | -1.30 |
Net Debt / FCF Ratio | - | -1.44 | -0.74 | 1.77 | -1.10 | 1.33 |
Asset Turnover | 0.62 | 0.59 | 0.59 | 0.61 | 0.60 | 0.47 |
Inventory Turnover | 2.32 | 2.09 | 1.80 | 2.84 | 4.01 | 3.59 |
Quick Ratio | 1.64 | 1.95 | 1.73 | 1.76 | 1.69 | 1.51 |
Current Ratio | 1.90 | 2.21 | 2.01 | 2.10 | 1.84 | 1.63 |
Return on Equity (ROE) | 18.77% | 16.24% | 10.06% | 9.94% | 13.62% | 25.41% |
Return on Assets (ROA) | 7.78% | 6.73% | 6.26% | 4.11% | 3.62% | 1.38% |
Return on Invested Capital (ROIC) | 22.70% | 18.77% | 15.42% | 10.83% | 10.15% | 4.14% |
Return on Capital Employed (ROCE) | 15.10% | 12.50% | 12.70% | 8.70% | 7.80% | 3.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.43% | 4.81% | 4.35% | 4.47% | 3.40% | 7.83% |
FCF Yield | - | 5.96% | 6.16% | -2.08% | 3.70% | -2.14% |
Dividend Yield | 1.72% | 1.71% | 2.49% | 2.80% | 1.70% | 2.28% |
Payout Ratio | - | 29.07% | 55.61% | 58.65% | 42.04% | 25.96% |
Buyback Yield / Dilution | -3.08% | 1.25% | 3.40% | 0.45% | -0.34% | -9.14% |
Total Shareholder Return | -1.36% | 2.96% | 5.88% | 3.25% | 1.36% | -6.86% |